All News

Psoriasis, an inflammatory skin disease, is often linked to many comorbidities that affect treatment decisions and the overall management of the disorder, according to new research.

There is an association between the presence of cardiovascular risk factors in adolescence and a lower cognition later in life, regardless of the exposure experienced during adulthood.

The progressive neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and Parkinson disease share the risk factors of increased age and male sex, but new research indicates there is also an association between a patient’s occupation and the mortality rate from these diseases.

A new blood biomarker demonstrates its ability to detect pancreatic cancer earlier, which can lead to better treatment and outcomes, according to a study published in Science Translational Medicine.

According to researchers, additional preventative efforts are necessary to curtail the increasing rate of non-healthcare facility medication errors that can result in serious patient outcomes.

The healthcare industry remains awash in paper, and the sector has been slow to recognize the demands on consumers or how much they expect their payment choices to match what they see elsewhere in their lives.

This week, the top managed care news included insurers staying away from HealthCare.gov, where you live can affect your chance of surviving cancer, and a new deal could help people on Medicare with diabetes.

Digital providers have been seen as crucial to scaling the Diabetes Prevention Program to the 22 million seniors with prediabetes. Medicare spends $1 out of every $3 on diabetes, and disease prevention is essential to lowering overall healthcare spending.

Coverage of our peer-reviewed research in the healthcare and mainstream press.

New research suggests that a high fat diet could reduce the bacteria of the gut and, therefore, fight against the harmful inflammation that Crohn’s disease patients experience.

A new study examines the impact that a pharmaceutical’s designation as an orphan drug can have on its manufacturer’s stock prices, and finds that the largest returns were for oncology drugs.

The new long-acting muscarinic antagonist and long-acting beta-agonist (LAMA/LABA) fixed dose combination (FDC) inhaler may be a better option than inhaled corticosteroids (ICS) for long-term use.

A partnership of federal departments announced a coordinated takedown of hundreds of defendants accused of perpetrating schemes to defraud Medicare and illegally distributing opioids.

The survey found a jump in physician burnout since 2013 and a gap in the commitment to combat medical errors, a problem that persists despite the movement toward quality measures.

The comittee voted 17-0 in favor of the Amgen/Allergan bevacizumab biosimilar candidate, ABP 215, and 16-0 in favor of Mylan’s trastuzumab biosimilar candidate, MYL-1401O.

In response to a request from the FDA, the National Academies of Sciences, Engineering, and Medicine has issued a report outlining the current body of research on chronic pain and opioid use disorder, including recommendations on what steps the regulatory agency can take in response to the ongoing epidemic.

The partnership is the latest pairing in the diabetes technology sector, as companies compete to offer ever less invasive tools for disease management.

A new draft report from the Institute for Clinical and Economic Review (ICER) evaluates the evidence on the effectiveness and value of 3 drugs used to treat ovarian cancer.

The revised bill still converts Medicaid to a block grant program but gives states some flexibility, sets aside billions to combat the opioid crisis, and gives health savings accounts a bigger role.

A new vaccine may be able to reduce low-density lipoprotein (LDL) cholesterol and, therefore, protect people against the risk of cardiovascular disease.

There is an association between being overweight, abdominal obesity, and a high body fat percentage with a greater risk of rheumatoid arthritis (RA) for women but not men, according to a study.

CTL019 was unanimously approved by FDA’s Oncologic Drugs Advisory Committee (ODAC) for the treatment of children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

The House of Representatives passed the FDA Reauthorization Act of 2017 with a voice vote, indicating the strong levels of bipartisan support for the bill that will reauthorize the user fee programs that fund the FDA.

The agreement paves the way for those over age 65 to gain access to continuous glucose monitoring, following a historic policy change.

Blinatumomab is now fully approved as a treatment for relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), following FDA assessment of new trial data on survival outcomes and its use in certain clinical subgroups.

Severe hemophilia often results in a significant economic and psychological burden on patients, caregivers, and the healthcare system as a whole, according to recent research from Europe.